Kabeer Aziz
Principal @ Adjuvant Capital
New York, United States
Kabeer Aziz is a Series C investor at Adjuvant Capital in New York focused on Biotechnology and Medical. Kabeer Aziz - Associate @ Global Health Investment Fund (GHIF)
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Kabeer Aziz invests in
Stages Kabeer Aziz invests in
Countries Kabeer Aziz invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Health Care 2 (33%)
- Wellness 1 (17%)
- Biopharma 1 (17%)
Stage
- Series C 2 (33%)
- Series A 1 (17%)
- Series B 1 (17%)
- Funding Round 1 (17%)
Country
- Denmark 1 (17%)
- Switzerland 1 (17%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M / Oct 11, 2023 | ||
| LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $36.5M / Series A / Oct 09, 2023 | ||
| Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M / Series C / Dec 15, 2022 | ||
| Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract. | $52M / Series C / Dec 06, 2022 | ||
| Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract. | $92M / Series C / May 27, 2021 | ||
| Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.6M / Series B / Dec 15, 2020 |
Co-Investors
About Adjuvant Capital
Adjuvant Capital is a life sciences investment firm focused on global health. The company makes $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Adjuvant Capital was founded in 2012 by Charlie Petty, Glenn Rockman, and Kabeer Aziz and is based in New York.
Adjuvant Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Glenn Rockman
Founder and Managing Partner
|
|||
Michael Chang
Principal
|
|||
Charlie Petty
Principal
|
|||
Jenny Yip
Managing Partner
|
|||
|
Kabeer Aziz
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kabeer Aziz invest in?
Kabeer Aziz invests primarily in Biotechnology, Medical and Health Care startups, most often at Series C and Series A stage. Most of the 6 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kabeer Aziz?
Public channels for Kabeer Aziz include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kabeer Aziz last invest?
The most recent investment recorded for Kabeer Aziz closed in Oct 2023. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
